Trial Profile
A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Apalutamide (Primary) ; Enzalutamide (Primary) ; KPG-121 (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Kangpu Biopharmaceuticals
- 16 Jul 2023 Status changed from active, no longer recruiting to completed.
- 19 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Jun 2023.
- 01 May 2023 Planned End Date changed from 1 Apr 2023 to 1 May 2023.